A more complete version of a study given at ASCO in early June.
ABT-199/GDC-0199 Phase 1 study from EHA (Euro... - CLL Support
ABT-199/GDC-0199 Phase 1 study from EHA (European-Hematology-Association)
Written by
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Phase 2 CLL2-BAAG trial results from the German CLL Study Group
Some very encouraging news for those with unmutated IGHV and/or TP53 aberrations, who are wondering...
Pirtobrutinib(loxo-305) Interesting study
Hi All,
If you haven’t seen it, here is a interesting study done at the James Center at Ohio State...
Update on PCYC-1115-CA Randomised, Phase 3 study of Ibrutinib/Imbruvica versus Chlorambucil in Patients 65 yrs and untreated with CLL/SLL.
This is the first significant change to report, other than the reduction of lymph nodes after the...
Leukemia & Lymphoma Society COVID-19 vaccine safety data is now available ; vaccine antibody data expected later in 2021
On behalf of the Leukemia & Lymphoma Society, thank you again for joining the LLS National Patient...
Related Posts
CT scan 2015 info update #1- Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL
- Real-World Study Shows Limited Implementation of Reccomended Biomarker Testing in CLL
Triplet Regimen Shows Promise in CLL -Zanubrutinib, obinutuzumab, & venetoclax combo achieves rapid undetectable MRD -MedPageToday -07/07/20
Stress Exacerbates CLL And Speeds Up Its Progression
